130 related articles for article (PubMed ID: 24329937)
1. A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin.
Ferenci P; Aires R; Ancuta I; Arohnson A; Cheinquer H; Delic D; Gschwantler M; Larrey D; Tallarico L; Schmitz M; Tatsch F; Ouzan D
Liver Int; 2014 Nov; 34(10):1550-9. PubMed ID: 24329937
[TBL] [Abstract][Full Text] [Related]
2. A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.
Asselah T; Thompson AJ; Flisiak R; Romero-Gomez M; Messinger D; Bakalos G; Shiffman ML
PLoS One; 2016; 11(3):e0150569. PubMed ID: 26991780
[TBL] [Abstract][Full Text] [Related]
3. Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies.
Asselah T; Esmat G; Sanai FM; Goulis I; Messinger D; Bakalos G; Waked I
Adv Ther; 2016 Oct; 33(10):1797-1813. PubMed ID: 27517563
[TBL] [Abstract][Full Text] [Related]
4. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.
Zeuzem S; Rodríguez-Torres M; Rajender Reddy K; Marcellin P; Diago M; Craxi A; Pockros P; Rizzetto M; Bernstein D; Shiffman ML; Lin A; Tatsch F; Hadziyannis S
J Viral Hepat; 2012 Nov; 19(11):766-74. PubMed ID: 23043383
[TBL] [Abstract][Full Text] [Related]
5. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.
Foster GR; Coppola C; Derbala M; Ferenci P; Orlandini A; Reddy KR; Tallarico L; Shiffman ML; Ahlers S; Bakalos G; Hassanein T;
PLoS One; 2016; 11(3):e0151703. PubMed ID: 27018988
[TBL] [Abstract][Full Text] [Related]
6. Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort.
Aronsohn A; Ancuta I; Caruntu F; Coppola C; Delic D; Digiacomo A; Dusheiko GM; Lengyel G; Marcellin P; Orlandini A; Pruthi J; Silva GF; Tallarico L; Schmitz M; Tatsch F; Korner E; Cheinquer H
J Viral Hepat; 2014 May; 21(5):377-80. PubMed ID: 24131506
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
[TBL] [Abstract][Full Text] [Related]
9. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
10. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
Foster GR; Fried MW; Hadziyannis SJ; Messinger D; Freivogel K; Weiland O
Scand J Gastroenterol; 2007 Feb; 42(2):247-55. PubMed ID: 17327945
[TBL] [Abstract][Full Text] [Related]
11. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
[TBL] [Abstract][Full Text] [Related]
12. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
Parise E; Cheinquer H; Crespo D; Meirelles A; Martinelli A; Sette H; Gallizi J; Silva R; Lacet C; Correa E; Cotrim H; Fonseca J; Paraná R; Spinelli V; Amorim W; Tatsch F; Pessoa M;
Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
[TBL] [Abstract][Full Text] [Related]
14. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.
Marcellin P; Reau N; Ferenci P; Hadziyannis S; Messinger D; Tatsch F; Jensen D
J Hepatol; 2012 Jun; 56(6):1276-82. PubMed ID: 22314423
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
[TBL] [Abstract][Full Text] [Related]
16. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
Nelson DR; Zeuzem S; Andreone P; Ferenci P; Herring R; Jensen DM; Marcellin P; Pockros PJ; Rodríguez-Torres M; Rossaro L; Rustgi VK; Sepe T; Sulkowski M; Thomason IR; Yoshida EM; Chan A; Hill G
Ann Hepatol; 2012; 11(1):15-31. PubMed ID: 22166557
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
18. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Pockros PJ; Nelson D; Godofsky E; Rodriguez-Torres M; Everson GT; Fried MW; Ghalib R; Harrison S; Nyberg L; Shiffman ML; Najera I; Chan A; Hill G
Hepatology; 2008 Aug; 48(2):385-97. PubMed ID: 18570306
[TBL] [Abstract][Full Text] [Related]
19. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
20. High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.
Heo NY; Lim YS; Lee HC; Lee YS; Kim KM; Byun KS; Han KH; Lee KS; Paik SW; Yoon SK; Suh DJ
Clin Mol Hepatol; 2013 Mar; 19(1):60-9. PubMed ID: 23593611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
